H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on FibroBiologics (FBLG) to $10 from $12 and keeps a Buy rating on the shares. The firm says the company’s progress continues across therapeutic fibroblast development.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG: